SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Psychopharmacology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Brazell, C.
Right arrow Articles by Traub, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Brazell, C.
Right arrow Articles by Traub, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The scopolamine model of dementia: chronic transdermal administration

C. Brazell

Neuroscience Research Centre, Merck, Sharp and Dohme, Terlings Park, Eastwick Road, Harlow, Essex, UK

G.C. Preston

Neuroscience Research Centre, Merck, Sharp and Dohme, Terlings Park, Eastwick Road, Harlow, Essex, UK

C. Ward

Neuroscience Research Centre, Merck, Sharp and Dohme, Terlings Park, Eastwick Road, Harlow, Essex, UK

C.R. Lines

Neuroscience Research Centre, Merck, Sharp and Dohme, Terlings Park, Eastwick Road, Harlow, Essex, UK

M. Traub

Neuroscience Research Centre, Merck, Sharp and Dohme, Terlings Park, Eastwick Road, Harlow, Essex, UK

The transient impairments of memory produced by the muscarinic antagonist scopolamine have been adopted as a pharmacological model of Alzheimer-type dementia in normal volunteers. In this study we examined the effects of chronic (72 h) transdermal administration of scopolamine on memory, attention, sedation and visual function. The transdermal patches provided constant plasma levels of scopolamine for the duration of the study. Indices of the peripheral effects of scopolamine (visual near-point and pupil size) showed impairments that were sustained for 3 days. However, measures of sedation and memory revealed impairments that were maximal the day after patch application and which were no longer present 3 days after application. This pattern of results is discussed in relation to pharmacological modelling of Alzheimer's disease.

Journal of Psychopharmacology, Vol. 3, No. 2, 76-82 (1989)
DOI: 10.1177/026988118900300205
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement